{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:55:54Z","timestamp":1780491354239,"version":"3.54.1"},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T00:00:00Z","timestamp":1490227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>We determined the pyridostigmine prescription pattern in a population of patients with myasthenia gravis (MG). A descriptive cross\u2010sectional study was conducted by using a prescription database of 3.5 million individuals from which patients who had been diagnosed with MG and for whom pyridostigmine had been prescribed were selected. A total of 306 outpatients with MG were found, and 258 were receiving pyridostigmine (mean age 53.0\u2009\u00b1\u200918.0 years). The calculated prevalence of MG was 86.7 cases per million persons. Monotherapy was used by 53.1% of the patients, prednisolone was used by 21.7%, and 30.2% used other immunomodulators. Medications for other comorbidities were taken by 74.8% of the patients, and 43.4% had prescriptions that could potentially trigger worsening symptoms. Pyridostigmine is being prescribed at doses close to the defined daily doses predominantly as monotherapy. A high proportion of patients were also prescribed a medication that could aggravate their condition, including some that can trigger a myasthenic crisis.<jats:italic>Muscle Nerve<\/jats:italic><jats:bold>56<\/jats:bold>: 1041\u20131046, 2017<\/jats:p>","DOI":"10.1002\/mus.25625","type":"journal-article","created":{"date-parts":[[2017,2,18]],"date-time":"2017-02-18T16:06:41Z","timestamp":1487434001000},"page":"1041-1046","source":"Crossref","is-referenced-by-count":13,"title":["Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis"],"prefix":"10.1002","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-0936","authenticated-orcid":false,"given":"Jorge Enrique","family":"Machado\u2010Alba","sequence":"first","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Farmacoepidemiolog\u00eda y Farmacovigilancia, Universidad Tecnol\u00f3gica de Pereira Audifarma S.A., Pereira, Calle 105 No. 14\u2010140, Pereira, Colombia South America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Felipe","family":"Calvo\u2010Torres","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Farmacoepidemiolog\u00eda y Farmacovigilancia, Universidad Tecnol\u00f3gica de Pereira Audifarma S.A., Pereira, Calle 105 No. 14\u2010140, Pereira, Colombia South America"},{"name":"Resident of clinical neurology, Universidad Nacional de Colombia Bogot\u00e1, Colombia South Am\u00e9rica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Gaviria\u2010Mendoza","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Farmacoepidemiolog\u00eda y Farmacovigilancia, Universidad Tecnol\u00f3gica de Pereira Audifarma S.A., Pereira, Calle 105 No. 14\u2010140, Pereira, Colombia South America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Augusto Mej\u00edA\u2010V\u00e9lez","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Farmacoepidemiolog\u00eda y Farmacovigilancia, Universidad Tecnol\u00f3gica de Pereira Audifarma S.A., Pereira, Calle 105 No. 14\u2010140, Pereira, Colombia South America"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,23]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.01.003"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-2-44"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-10-46"},{"issue":"11","key":"e_1_2_5_5_1","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.33588\/rn.3411.2001523","article-title":"Prevalencia de la miastenia grave en Antioquia, Colombia","volume":"34","author":"S\u00e1nchez J","year":"2002","journal-title":"Rev Neurol"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpem.2008.02.001"},{"issue":"5","key":"e_1_2_5_7_1","first-page":"1413","article-title":"Myasthenia gravis and Lambert\u2010Eaton myasthenic syndrome","volume":"20","author":"Sanders DB","year":"2014","journal-title":"Continuum"},{"issue":"1","key":"e_1_2_5_8_1","first-page":"35","article-title":"Myasthenia gravis: immunopathogenesis, diagnosis, and management","volume":"15","author":"Meriggioli MN","year":"2009","journal-title":"Continuum"},{"issue":"2","key":"e_1_2_5_9_1","first-page":"CD006986","article-title":"Acetylcholinesterase inhibitor treatment for myasthenia gravis","author":"Mehndiratta MM","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21319"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03085.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcn152"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1941875210382918"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.4997\/JRCPE.2011.111"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00127893-200201000-00002"},{"key":"e_1_2_5_16_1","volume-title":"Medications and myasthenia gravis (a reference for health care professionals)","author":"Mehrizi M","year":"2012"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.80a.13044"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cacc.2007.01.006"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12439"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9562.1000317"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regg.2009.03.017"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2015.06.015"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5256-6"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.25625","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.25625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T14:09:56Z","timestamp":1749996596000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.25625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,23]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1002\/mus.25625"],"URL":"https:\/\/doi.org\/10.1002\/mus.25625","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,23]]}}}